Going forward..., page-1529

https://**promotion blocked**/health/mesoblast-has-long-been-the-one-poster-child-for-stem-cell-therapy-now-cynata-and-other-asx-stocks-have-emerged/

"A Phase 3 clinical trial for osteoarthritis which is funded by a NHMRC grant has progressed the furthest, while a Phase 2 trial in COVID-19 is ongoing.

Meanwhile a Phase 1 study in GvHD, which was published in prestigious journal Nature Medicine, is probably the closest to commercialisation according to Dr Macdonald."

As Ross said at the end of 2021, above, GvHD is probably closest to commercialisation for CYP. Now this has yet to commence a P2 with the FDA and hinges on a 'partner' willing to pay for the whole lot (without expectation of ownership) and on the condition that CYP runs the FDA trials from Australia, without ANY experience in running FDA trials and limited experience in running successful trials, period.

And that 'is probably the closest to commercialsation' says Ross.

Ross has also said, a few short months ago, that this same FDA P2 trial will start by the end of this year. Now, it's mid Oct and there is no announcement of a partner that is essential in paying for this FDA P2 trial. Are people aware of the processes involved in a FDA trial at all? Ross made that call in May 2022!!

There is a T20 holder here (actually nominates herself as T14) that has been buying big since late 2021.





You can't say Ross didn't inform SH's.